Literature DB >> 7740322

Management of malignant pleural effusions.

J C Ruckdeschel1.   

Abstract

Malignant pleural effusions are a common complication of advanced cancer, particularly breast and lung cancers. Clinical algorithms for the diagnosis and management of malignant pleural effusions form a framework for the cost-effective provision of meaningful palliation. When the entire episode of care is considered, the optimal therapy for malignant pleural effusions appears to be tube thoracostomy followed by intrapleural bleomycin. Alternative strategies for the delivery of intrapleural therapy (eg, soft catheters) and new intrapleural agents currently are being compared with standard therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7740322

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  12 in total

Review 1.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

2.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion.

Authors:  Mingchen Ba; Hui Long; Yuandong Wang; Yunqiang Tang; Yinbing Wu; Xiangliang Zhang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

4.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

5.  Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.

Authors:  C Y Hu; Y H Zhang; T Wang; L Chen; Z H Gong; Y S Wan; Q J Li; Y S Li; B Zhu
Journal:  Clin Exp Immunol       Date:  2016-08-23       Impact factor: 4.330

6.  A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.

Authors:  Daniel H Sterman; Adri Recio; Andrew R Haas; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Edmund Moon; Luana Pereira; Xinzhong Wang; Daniel F Heitjan; Leslie Litzky; Carl H June; Robert H Vonderheide; Richard G Carroll; Steven M Albelda
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

Review 7.  Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Authors:  Andrew J Sweatt; Arthur Sung
Journal:  Curr Treat Options Oncol       Date:  2014-12

8.  Homocysteine: new tumor marker in pleural fluid.

Authors:  Jose D Santotoribio; Consuelo Cañavate-Solano; Angela Garcia-de la Torre; Luis Del Valle-Vazquez; Francisco Arce-Matute; Juan F Cuadros-Muñoz; Maria J Sanchez del Pino; Manuel J Bandez-Ruiz; Carmen Piñuela-Rojas; Santiago Perez-Ramos
Journal:  Tumour Biol       Date:  2015-05-09

Review 9.  Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.

Authors:  Siyamek Neragi-Miandoab
Journal:  Support Care Cancer       Date:  2008-02-08       Impact factor: 3.603

10.  Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion.

Authors:  Islam M Ibrahim; Ahmed L Dokhan; Alaa A El-Sessy; Mohammed F Eltaweel
Journal:  J Cardiothorac Surg       Date:  2015-05-01       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.